Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18 2024 - 8:05AM
Business Wire
– Dr. Etkin recognized as a Bay Area winner out
of 26 finalists by an independent panel of judges –
– Entrepreneur Of The Year celebrates ambitious
entrepreneurs who are shaping the future across all industries
–
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced
that Amit Etkin, M.D., Ph.D., founder and CEO, was named an
Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY. Now
in its 38th year, Entrepreneur Of The Year is the preeminent
competitive business award for audacious leaders who disrupt
markets, revolutionize sectors, and have a transformational impact
on lives. Over the past four decades, the program has recognized
daring entrepreneurs with big ideas and bold actions that reshape
our world, across all industries and sectors.
Dr. Etkin was one of nine entrepreneurs selected as a Bay Area
award winner by an independent panel of judges. The winners were
evaluated out of 26 finalists based on their demonstration of
building long-term value through entrepreneurial spirit, purpose,
growth and impact, among other core contributions and attributes.
Finalists were identified from a pool of roughly 1,000 nominated
candidates.
“I am honored to be named an EY Entrepreneur of the Year award
winner among other esteemed entrepreneurs, CEOs, and business
leaders in the Bay Area,” said Amit Etkin, M.D., Ph.D., founder and
CEO of Alto Neuroscience. “When I launched Alto out of my Stanford
lab in 2019, I was motivated by a core belief in the power of
industry and innovation to catalyze meaningful change for patients.
This recognition is a strong testament to the broad belief in
Alto's mission to make precision psychiatry a reality, our
company’s progress to date, and the invaluable contributions of our
entire team.”
Entrepreneur Of The Year honors many different types of business
leaders for their ingenuity, courage, entrepreneurial spirit, and
global impact. The program celebrates original founders who
bootstrapped their business from inception or who raised outside
capital to grow their company; transformational CEOs who infused
innovation into an existing organization to catapult its
trajectory; and multigenerational family business leaders who
reimagined a legacy business model to fortify it for the
future.
Regional award winners were announced on June 14, 2024, and
became lifetime members of an esteemed community of Entrepreneur Of
The Year alumni from around the world. Winners will now be
considered by the National judges for the Entrepreneur Of The Year
National Awards, which will be presented in November at the annual
Strategic Growth Forum®, one of the nation’s most prestigious
gatherings of high-growth, market-leading companies.
About Entrepreneur Of The Year®
Founded in 1986, Entrepreneur Of The Year® has celebrated more
than 11,000 ambitious visionaries who are leading successful,
dynamic businesses in the US, and it has since expanded to nearly
80 countries and territories globally.
The US program consists of 17 regional programs whose panels of
independent judges select the regional award winners every June.
Those winners compete for national recognition at the Strategic
Growth Forum® in November where National finalists and award
winners are announced. The overall National winner represents the
US at the World Entrepreneur Of The Year® competition. Visit
ey.com/us/eoy.
About EY
EY exists to build a better working world, helping to create
long-term value for clients, people and society and build trust in
the capital markets. Enabled by data and technology, diverse EY
teams in over 150 countries provide trust through assurance and
help clients grow, transform and operate. Working across assurance,
consulting, law, strategy, tax and transactions, EY teams ask
better questions to find new answers for the complex issues facing
our world today.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company
with a mission to redefine psychiatry by leveraging neurobiology to
develop personalized and highly effective treatment options. Alto’s
Precision Psychiatry Platform™ measures brain biomarkers by
analyzing EEG activity, neurocognitive assessments, wearable data,
and other factors to better identify which patients are more likely
to respond to Alto product candidates. Alto’s clinical-stage
pipeline includes novel drug candidates in depression, PTSD,
schizophrenia, and other mental health conditions. For more
information, visit www.altoneuroscience.com or follow Alto on
X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618810704/en/
Investor Contact Nick Smith
investors@altoneuroscience.com
Media Contact Jordann Merkert
media@altoneuroscience.com
Alto Neuroscience (NYSE:ANRO)
Historical Stock Chart
From May 2024 to Jun 2024
Alto Neuroscience (NYSE:ANRO)
Historical Stock Chart
From Jun 2023 to Jun 2024